Clinical Trials

Inclusion Criteria:

• Part A: Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option. Part B: Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which platinum/taxane-based combination therapy is a rational treatment option.
• Age ≥18 years
• ECOG Performance Status ≤ 1.
• Estimated life expectancy of at least 12-weeks;
• Measurable disease as per RECIST guideline (Version 1.1);
• Adequate organ and immune system function as indicated by laboratory tests obtained ≤ 2 weeks prior to dosing.
• Women of child bearing potential practicing an acceptable method of birth control.
• Willing to participate and give written informed consent.

Exclusion Criteria:

• Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia (CIN), or in situ cervical cancer (CIS)
• Known hypersensitivity to the study drugs
• Treatment with any anti-cancer agents within 28 days of study entry
• Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy
• Pre-existing peripheral neuropathy (grade 1 or higher)
• Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study